PMID: 42225305

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Michalak Wojciech, Bøg Martin, Bendixen Theiss, Chowdhury Rohan, Cowley Phoebe, Laugesen Christian, Rathor Naveen, Kushner Robert F

Diabetes, obesity & metabolism · 2026

Vol. 28, Issue 8, pp. 7247-7256

View on PubMedDOI

This entry links to third-party literature. For research use only.

HumansSemaglutideGlucagon-Like PeptidesFemaleMaleObesityMiddle AgedAdministration, OralWeight LossAdult

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.